Investment Analysts’ Weekly Ratings Updates for Axsome Therapeutics (AXSM)

Several brokerages have updated their recommendations and price targets on shares of Axsome Therapeutics (NASDAQ: AXSM) in the last few weeks:

• 8/11/2026 – Axsome Therapeutics had its price target lowered by Royal Bank Of Canada from $304.00 to $297.00. They now have an “outperform” rating on the stock.
• 8/11/2026 – Axsome Therapeutics had its price target raised by Morgan Stanley from $242.00 to $251.00. They now have an “equal weight” rating on the stock.
• 8/11/2026 – Axsome Therapeutics had its price target raised by Guggenheim from $260.00 to $275.00. They now have a “buy” rating on the stock.
• 8/11/2026 – Axsome Therapeutics is now covered by UBS Group AG. They set a “market perform” rating on the stock.
• 8/11/2026 – Axsome Therapeutics had its price target raised by Wells Fargo & Company from $255.00 to $256.00. They now have an “overweight” rating on the stock.
• 8/11/2026 – Axsome Therapeutics had its price target raised by Needham & Company LLC from $267.00 to $268.00. They now have a “buy” rating on the stock.
• 7/31/2026 – Axsome Therapeutics had its price target lowered by Mizuho from $310.00 to $306.00. They now have an “outperform” rating on the stock.
• 7/20/2026 – Axsome Therapeutics is now covered by BMO Capital Markets. They set an “outperform” rating and a $310.00 price target on the stock.
• 7/20/2026 – Axsome Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/20/2026 – Axsome Therapeutics was upgraded by BMO Capital Markets to “strong-buy”.
• 7/17/2026 – Axsome Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/15/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $290.00 price target on the stock.
• 7/8/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $290.00 price target on the stock.
• 7/7/2026 – Axsome Therapeutics had its price target raised by Royal Bank Of Canada from $302.00 to $304.00. They now have an “outperform” rating on the stock.
• 6/17/2026 – Axsome Therapeutics had its price target raised by TD Cowen from $275.00 to $300.00. They now have a “buy” rating on the stock.
• 6/15/2026 – Axsome Therapeutics was upgraded by Truist Financial Corporation to “strong-buy”.

Insider Buying and Selling

In related news, Director Mark Coleman sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $230.30, for a total transaction of $1,381,800.00. Following the completion of the transaction, the director owned 35,140 shares in the company, valued at $8,092,742. The trade was a 14.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Susan Mahony sold 300 shares of the company’s stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $237.21, for a total value of $71,163.00. Following the transaction, the director owned 1,129 shares of the company’s stock, valued at approximately $267,810.09. The trade was a 20.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 200,766 shares of company stock valued at $46,685,646 over the last three months. 20.60% of the stock is owned by company insiders.

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.